{"entity":{"id":"nct05413018","kind":"trial","name":"An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission","aka":[],"tldr":"A phase 2 trial of CC-486 in acute myeloid leukaemia, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission is a phase 2 interventional study registered as NCT05413018 by Bristol-Myers Squibb, with 34 participants enrolled, started 2022-08-19 and due to reach its primary completion in 2025-10-31. Interventions recorded: CC-486.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05413018","url":"https://clinicaltrials.gov/study/NCT05413018"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05413018","phase":"2","setting":"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine (CC-486) Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Chinese Patients With Acute Myeloid Leukemia in Complete Remission","sponsor":"Bristol-Myers Squibb","enrolled":34,"outcomes":[]},"route":"/trials/nct05413018/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}